Preferences help
enabled [disable] Abstract
Number of results
2016 | 63 | 3 | 459-467
Article title

Hepatokines and non-alcoholic fatty liver disease

Title variants
Languages of publication
Nowadays non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver pathology both in adults and children. NAFLD manifestation ranges from a simple liver steatosis to steatohepatitis (nonalcoholic steatohepatitis - NASH), which may progress to advanced fibrosis, cirrhosis and end-stage liver disease. Due to the coexistence of visceral obesity, insulin resistance and dyslipidemia, NAFLD is considered to be the hepatic manifestation of metabolic syndrome. In recent years, in the pathogenesis of metabolic syndrome, type 2 diabetes mellitus, cardiovascular disease and also NAFLD, more and more attention has been paid to the so-called organokines, proteins with both paracrine or/and endocrine activities. These include most known adipokines (mainly produced by adipose tissue), myokines (mainly produced by skeletal muscles) and hepatokines exclusively or predominantly produced by the liver. It was shown that the liver may affect the lipids and glucose metabolism by hepatokines released into the blood and NAFLD seems to be associated with altered hepatokines production. Fetuin-A, fibroblast growth factor-21 (FGF-21), selenoprotein P, sex hormone-binding globulin (SHBG), angiopoietin-related growth factor (also known as angiopoietin-related protein 6) and leukocyte derived chemotaxin 2 (LECT2) are considered as the most important hepatokines. In this review, we provide an overview of the main hepatokines and we summarize the association of liver-derived proteins with the development and progression of NAFLD.
Physical description
  • Department of Pediatrics, Gastroenterology and Allergology, Medical University of Bialystok, Poland
  • Department of Pediatrics, Gastroenterology and Allergology, Medical University of Bialystok, Poland
  • Medical Institute, Lomza State University of Applied Sciences, Poland
  • Department of Pediatrics, Gastroenterology and Allergology, Medical University of Bialystok, Poland
  • Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Poland
  • Adams LA, Angulo P (2005) Recent concepts in non-alcoholic fatty liver disease. Diabet Med 22: 1129-1133. doi: 10.1111/j.1464-5491.2005.01748.x.
  • Alisi A, Ceccarelli S, Panera N, Prono F, Petrini S, De Stefanis C, Pezzullo M, Tozzi A, Villani A, Bedogni G, Nobili V (2013) Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS One 8: e67160. doi: 10.1371/journal.pone.0067160.
  • Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, Rossi B, Le Cam A (1989) Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 58: 631-640. doi: 10.1016/0092-8674(89)90098-6.
  • Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPAR alpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5: 426-437. doi: 10.1016/j.cmet.2007.05.002.
  • Berube D, Seralini GE, Gagne R, Hammond GL (1990) Localisation of the human sex hormone-binding globulin gene (SHGB) to the short arm of chromosome 17 (17p12-13). Cytogenet Cell Genet 54: 65-67.
  • Birkenfeld AL, Shulman GI (2014) Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59: 713-723. doi: 10.1002/hep.26672.
  • Bonnet F, Velayoudom Cephise FL, Gautier A, Dubois S, Massart C, Camara A, Larifla L, Balkau B, Ducluzeau PH (2013) Role of sex steroids, intrahepatic fat and liver enzymes in the association between SHBG and metabolic features. Clin Endocrinol (Oxf) 79: 517-522. doi: 10.1111/cen.12089.
  • Burk RF, Hill KE (2005) Selenoprotein P: an extracellular protein with unique physical characteristic and a role in selenium homeostasis. Annu Rev Nutr 25: 215-235. doi: 10.1146/annurev.nutr.24.012003.132120.
  • Burke A, Lucey MR (2004) Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 4: 686-693. doi: 10.1111/j.1600-6143.2004.00432.x.
  • Caldwell S, Argo C (2010) The natural history of non-alcoholic fatty liver disease. Dig Dis 28: 162-168. doi: 10.1159/000282081.
  • Chartoumpekis DV, Ziros PG, Psyrogiannis AI, Papavassiliou AG, Kyriazopoulou VE, Sykiotis GP, Habeos IG (2011) Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice. Diabetes 60: 2465-2473. doi: 10.2337/db11-0112.
  • Choi HY, Hwang SY, Lee CH, Hong HC, Yang SJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi K (2013) Increased selenoprotein P levels in subjects with visceral obesity and nonalcoholic fatty liver disease. Diabetes Metab J 37: 63-71. doi: 10.4093/dmj.2013.37.1.63.
  • Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149: 6018-6027. doi: 10.1210/en.2008-0816.
  • Dasgupta S, Bhattacharya S, Biswas A, Majumdar SS, Mukhopadhyay S, Ray S, Bhattacharya S (2010) NF-kB mediates lipid-induced fetuin-A expression in hepatocytes that impaires adipocyte function effecting insulin resistance. Biochem J 429: 451-462. doi: 10.1042/BJ20100330.
  • Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W (2003) Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J 376: 135-145. doi: 10.1042/BJ20030676.
  • Diaz-Delfin J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F (2012) TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153: 4238-4245. doi: 10.1210/en.2012-1193.
  • Dogru T, Genc H, Tapan S, Aslan F, Ercin CN, Ors F, Kara M, Sertoglu E, Karslioglu Y, Bagci S, Kurt I, Sonmez A (2013) Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 78: 712-717. doi: 10.1111/j.1365-2265.2012.04460.x.
  • Dongiovanni P, Anstee QM, Valenti L (2013) Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 19: 5219-5238. doi: 10.2174/13816128113199990381.
  • Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML, Maratos-Flier E (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139: 456-463. doi: 10.1053/j.gastro.2010.04.054.
  • Ebert T, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M (2009) Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis. Metabolism 58: 547-551. doi: 10.1016/j.metabol.2008.11.016.
  • Ebert T, Kralisch S, Loessner U, Jessnitzer B, Stumvoll M, Fasshauer N, Tonjes A (2014) Relationship between serum levels of angiopoietin-related growth factor and metabolic risk factors. Horm Metab Res 46: 685-690. doi: 10.1055/s-0034-1382078.
  • Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128: 2436-2443. doi: 10.1002/ijc.25797.
  • Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, Lundasen T, Kharitonenkov A, Schuppan D, Flier JS, Maratos-Flier E (2014) Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 147: 1073-1083. doi: 10.1053/j.gastro.2014.07.044.
  • Fletcher JA, Meers GM, Laughlin GM, Ibdah JA, Thyfault JP, Rector RS (2012) Modulating fibroblast growth factor 21 in hyperphagic OLATF rats with daily exercise and caloric restriction. Appl Physiol Nutr Metab 37: 1054-1062. doi: 10.1139/h2012-091.
  • Flechtner-Mors M, Schick A, Oeztuerk S, Haenle MM, Wilhelm M, Koenig W, Imhof A, Boehm BO, Graeter T, Mason RA, Kratzer W, Akinli AS, EMIL-Study Group (2014) Associations of fatty liver disease and other factors affecting serum SHBG concentrations: a population based study on 1657 subjects. Horm Metab Res 46: 287-293. doi: 10.1055/s-0033-1354369.
  • Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, Goetz R, Mohammadi M, Kuro-o M, Mangelsdorf DJ, Kliewer SA (2010) Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24: 2050-2064. doi: 10.1210/me.2010-0142.
  • Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18: 333-340. doi: 10.1016/j.cmet.2013.08.005.
  • Gaudio E, Nobili V, Franchitto A, Onori P, Carpino G (2012) Nonalcoholic fatty liver disease and atherosclerosis. Intern Emerg Med 7 (suppl 3): S297-S305. doi: 10.1007/s11739-012-0826-5.
  • Giannini C, Feldstein AE, Santoro N, Kim G, Kursawe R, Pierpont B, Caprio S (2013) Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab 98: 2993-3000. doi: 10.1210/jc.2013-1250.
  • Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Loberg EM, Haaland T, Konopski Z, Wium C, Aasheim ET, Johansen OE, Aukrust P, Halvorsen B, Birkeland KI (2012) Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol 166: 503-510. doi: 10.1530/EJE-11-0864.
  • Haukeland JW, Konopski Z, Eggesbo HB, von Volkmann HL, Raschpichler G, Bjoro K, Haaland T, Loberg EM, Birkeland K (2009) Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 44: 853-860. doi: 10.1080/00365520902845268.
  • Heinrichsdorff J, Olefsky JM (2012) Fetuin-A: the missing link in lipid-induced inflammation. Nat Med 18: 1182-1183. doi: 10.1038/nm.2869.
  • Heuer M, Kaiser GM, Kahraman A, Banysch M, Saner FH, Mathe Z, Gerken G, Paul A, Canbay A, Treckmann JW (2012) Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion 86: 107-113. doi: 10.1159/000339344.
  • Hill KE, Dasouki M, Phillips JA 3rd, Burk RF (1996) Human selenoprotein P gene maps to 5q31. Genomics 36: 550-551. doi: 10.1006/geno.1996.0505.
  • Hua X, Sun Y, Zhong Y, Feng W, Huang H, Wang W, Zhang T, Hu Y (2014) Low serum sex hormone-binding globulin is associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Clin Endocrinol (Oxf) 80: 877-883. doi: 10.1111/cen.12360.
  • Hui E, Xu A, Yang HB, Lam KS (2013) Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: role of adipokines. J Diabetes Investig 4: 413-425. doi: 10.1111/jdi.12093.
  • Jiang S, Yan C, Fang QC, Shao ML, Zhang YL, Liu Y, Deng YP, Shan B, Liu JQ, Li HT, Yang L, Zhou J, Dai Z, Liu Y, Jia WP (2014) Fibroblast growth factor 21 is regulated by the IREα-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J Biol Chem 289: 29751-29765. doi: 10.1074/jbc.M114.565960.
  • Jiang S, Zhang R, Li H, Fang Q, Jiang F, Hou X, Hu C, Jia W (2014) The single nucleotide polymorphism rs499765 is associated with fibroblast growth factor 21 and nonalcoholic fatty liver disease in Chinese population with normal glucose tolerance. J Nutrigenet Nutrigenomics 7: 121-129. doi: 10.1159/000367943.
  • Kadomatsu T, Tabata M, Oike Y (2011) Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases. FEBS J 278: 559-564. doi: 10.1111/j.1742-4658.2010.07979.x.
  • Kahraman A, Sowa JP, Schlattjan M, Sydor S, Pronadl M, Wree A, Beilfuss A, Kilicarslan A, Altinbas A, Bechmann LP, Syn WK, Gerken G, Canbay A (2013) Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients. Clin Sci (Lond) 125: 391-400. doi: 10.1042/CS20120542.
  • Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, Konigsrainer I, Konigsrainer A, Schick F, Fritsche A, Haring HU, Stefan N (2009) Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58: 2616-2623. doi: 10.2337/db09-0279.
  • Kavanagh K, Espeland MA, Sutton-Tyrrell K, Barinas-Mitchell E, El Khoudary SR, Wildman RP (2013) Liver fat and SHBG affect insulin resistance in midlife women: the study of women's health across the nation (SWAN). Obesity (Silver Spring) 21: 1031-1038. doi: 10.1002/oby.20077.
  • Khan MS, Knowles BB, Aden DP, Rosner W (1981) Secretion of testosterone-estradiol-binding globulin by a human hepatoma-derived cell line. J Clin Endocrinol Metab 53: 448-449. doi: 10.1210/jcem-53-2-448.
  • Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, Wroblewski VJ, Li S, Koester A, Ford AM, Coskun T, Dunbar JD, Cheng CC, Frye CC, Bumol TF, Moller DE (2013) Rational design of a fibroblast growth factor 21-based clinical candidate LY2405319. PLoS One 8: e58575. doi: 10.1371/journal.pone.0058575.
  • Kim SH, Kim KH, Kim HK, Kim MJ, Back SH, Konishi M, Itoh N, Lee MS (2015) Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia 58: 809-818. doi: 10.1007/s00125-014-3475-6.
  • Kitazawa M, Ohizumi Y, Oike Y, Hishinuma T, Hashimoto S (2007) Angiopoietin-related growth factor suppresses gluconeogenesis through the Akt/Forkhead box class 01-dependent pathway in hepatocytes. J Pharmacol Exp Ther 323: 787-793. doi: 10.1124/jpet.107.127530.
  • Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, Still CD, Gerhard GS, Han X, Dziura J, Petersen KF, Samuel VT, Shulman G (2011) Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 108: 16381-16385. doi: 10.1073/pnas.1113359108.
  • Lan F, Misu H, Chikamoto K, Takayama H, Kikuchi A, Mohri K, Takata N, Hayashi H, Matsuzawa-Nagata N, Takeshita Y, Noda H, Matsumoto Y, Ota T, Nagano T, Nakagen M, Miyamoto K, Takatsuki K, Seo T, Iwayama K, Tokuyama K, Matsugo S, Tang H, Saito Y, Yamagoe S, Kaneko S, Takamura T (2014) LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resitance. Diabetes 63: 1649-1664. doi: 10.2337/db13-0728.
  • Lazo M, Zeb I, Nasir K, Tracy RP, Budoff MJ, Ouyang P, Vaidya D (2015) Association between endogenous sex hormones and liver fat in a multiethnic study of atherosclerosis. Clin Gastroenterol Hepatol 13: 1686-1693. doi: 10.1016/j.cgh.2014.12.033.
  • Lebensztejn DM, Bialokoz-Kalinowska I, Klusek-Oksiuta M, Tarasow E, Wojtkowska M, Kaczmarski M (2014) Serum fetuin A concentration is elevated in children with non-alcoholic fatty liver disease. Adv Med Sci 59: 81-84. doi: 10.1016/j.advms.2013.08.003.
  • Lebensztejn DM, Wasilewska N, Bobrus-Chociej A, Werpachowska I, Tarasow E (2016) Fibroblast growth factor 21 concentration in obese children with nonalcoholic fatty liver disease. Hepatol Int 10 (suppl 1): 398-399 (abstract).
  • Lee J, Hong SW, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY (2014) Exendin-4 regulates lipid metabolism and fibroblast growth factor-21 in hepatic steatosis. Metabolism 63: 1041-1048. doi: 10.1016/j.metabol.2014.04.011.
  • Li H, Dong K, Fang Q, Hou X, Zhou M, Bao Y, Xiang K, Xu A, Jia W (2013) High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J Hepatol 58: 557-563. doi: 10.1016/j.jhep.2012.10.029.
  • Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, Jia W (2010) Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 53: 934-940. doi: 10.1016/j.jhep.2010.05.018.
  • Li H, Zhang J, Jia W (2013) Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology. Front Med 7: 25-30. doi: 10.1007/s11684-013-0244-8.
  • Li K, Li L, Yang M, Liu H, Boden G, Yang G (2012) The effects of fibroblast growth factor-21 knockdown and over-expression on its signaling pathway and glucose-lipid metabolism in vitro. Mol Cell Endocrinol 348: 21-26. doi: 10.1016/j.mce.2011.07.026.
  • Liu J, Xu Y, Hu Y, Wang G (2015) The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism 64: 380-390. doi: 10.1016/j.metabol.2014.11.009.
  • Malin SK, Mulya A, Fealy CE, Haus JM, Pagadala MR, Scelsi AR, Huang H, Flask CA, McCullough AJ, Kirwan JP (2013) Fetuin-A is linked to improved glucose tolerance after short-term exercise training in nonalcoholic fatty liver disease. J Appl Physiol 115: 988-994. doi: 10.1152/japplphysiol.00237.2013.
  • Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Goustin AS, Jen KL, Charron MJ, Jahnen-Dechent W, Grunberger G (2002) Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 51: 2450-2458. doi: 10.2337/diabetes.51.8.2450.
  • Misu H, Ishikura K, Kurita S, Takeshita Y, Ota T, Saito Y, Takahashi K, Kaneko S, Takamura T (2012) Inverse correlation between serum levels of selenoprotein P and adiponectin in patients with type 2 diabetes. PLoS One 7: e34952. doi: 10.1371/journal.pone.0034952.
  • Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S, Ishikura K, Ando H, Takeshita Y, Ota T, Sakurai M, Yamashita T, Mizukoshi E, Yamashita T, Honda M, Miyamoto K, Kubota T, Kubota N, Kadowaki T, Kim HJ, Lee IK, Minokoshi Y, Saito Y, Takahashi K, Yamada Y, Takakura N, Kaneko S (2010) A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab 12: 483-495. doi: 10.1016/j.cmet.2010.09.015.
  • Mori K, Emoto M, Inaba M (2012) Fetuin-A and the cardiovascular system. Adv Clin Chem 56: 175-195. doi: 10.1016/B978-0-12-394317-0.00010-8.
  • Mori K, Emoto M, Inaba M (2011) Fetuin-A: a multifunctional protein. Recent Pat Endocr Metab Immune Drug Discov 5: 124-146. doi: 10.2174/187221411799015372.
  • Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y (2006) Association of serum fetuin-A with insulin resistance in type-2 diabetic and nondiabetic subject. Diabetes Care 29: 468. doi: 10.2337/diacare.29.02.06.dc05-1484.
  • Mu J, Pinkstaff J, Li Z, Skidmore L, Li N, Myler H, Dallas-Yang Q, Putnam AM, Yao J, Bussell S, Wu M, Norman TC, Rodriguez CG, Kimmel B, Metzger JM, Manibusan A, Lee D, Zaller DM, Zhang BB, Dimarchi RD, Berger JP, Axelrod DW (2012) FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61: 505-512. doi: 10.2337/db11-0838.
  • Namkung J, Koh SB, Kong ID, Choi JW, Yeh BI (2011) Serum levels of angiopoietin-related growth factor are increased in metabolic syndrome. Metabolism 60: 564-568. doi: 10.1016/j.metabol.2010.05.013.
  • Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206. doi: 10.1016/S0167-4781(00)00067-1.
  • Oike Y, Akao M, Yasunaga K, Yamauchi T, Morisada T, Ito Y, Urano T, Kimura Y, Kubota Y, Maekawa H, Miyamoto T, Miyata K, Matsumoto S, Sakai J, Nakagata N, Takeya M, Koseki H, Ogawa Y, Kadowaki T, Suda T (2005) Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat Med 11: 400-408. doi: 10.1038/nm1214.
  • Oike Y, Yasunaga K, Ito Y, Matsumoto S, Maekawa H, Morisada T, Arai F, Nakagata N, Takeya M, Masuho Y, Suda T (2003) Angiopoietin-related growth factor (AGF) promotes epidermal proliferation, remodeling and regeneration. Proc Natl Acad Sci USA 100: 9494-9499. doi: 10.1073/pnas.1531901100.
  • Okumura A, Unoki-Kubota H, Matsushita Y, Shiga T, Moriyoshi Y, Yamagoe S, Kaburagi Y (2013) Increased serum leukocyte cell-derived chemotaxin 2 (LECT2) in obesity and fatty liver. Biosci Trends 7: 276-283. doi: 10.5582/bst.2013.v7.6.276.
  • Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A (2002) Leptin-replacement therapy for lipodystrophy. N Engl J Med 346: 570-578. doi: 10.1056/NEJMoa012437.
  • Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ (2012) Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J Clin Endocrinol Metab 97: 4717-4723. doi: 10.1210/jc.2012-2414.
  • Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C (2011) Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 17: 3082-3091. doi: 10.3748/wjg.v17.i26.3082.
  • Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, Ray S, Majumdar SS, Bhattacharya S (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18: 1279-1285. doi: 10.1038/nm.2851.
  • Parola M, Marra F (2011) Adipokines and redox signaling: impact on fatty liver disease. Antioxid Redox Signal 15: 461-483. doi: 10.1089/ars.2010.3848.
  • Pedersen KO (1944) Fetuin, a new globulin isolated from serum. Nature 154: 575. doi: 10.1038/154575a0.
  • Perry RJ, Samuel VT, Petersen KF, Shulman GI (2014) The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510: 84-91. doi: 10.1038/nature13478.
  • Peter A, Kantartzis K, Machann J, Schick F, Staiger H, Machicao F, Schleicher E, Fritsche A, Haring HU, Stefan N (2010) Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes 59: 3167-3173. doi: 10.2337/db10-0179.
  • Peter A, Kantartzis K, Machicao F, Machann J, Wagner S, Templin S, Konigsrainer I, Konigsrainer A, Schick F, Fritsche A, Haring HU, Stefan N (2012) Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content. Int J Obes (Lond) 36: 774-782. doi: 10.1038/ijo.2011.154.
  • Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, Dziura J, Lifton RP, Shulman GI (2010) Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 362: 1082-1089. doi: 10.1056/NEJMoa0907295.
  • Polyzos SA, Kountouras J, Tsatsoulis A, Zafeiriadou E, Katsiki E, Patsiaoura K, Zavos C, Anastasiadou VV, Slavakis A (2013) Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. Hormones (Athens) 12: 405-416.
  • Raddatz K, Turner N, Frangioudakis G, Liao BM, Pedersen DJ, Cantley J, Wilks D, Preston E, Hegarty BD, Leitges M, Raftery MJ, Biden TJ, Schmitz-Peiffer C (2011) Time-dependent effects of Prkce deletion on glucose hemostasis and hepatic lipid metabolism on dietary liver oversupplay in mice. Diabetologia 54: 1447-1456. doi: 10.1007/s00125-011-2073-0.
  • Reinehr T, Roth CL (2008) Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 93: 4479-4485. doi: 10.1210/jc.2008-1505.
  • Reinehr T, Woelfle J, Wunsch R, Roth CL (2012) Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 97: 2143-2150. doi: 10.1210/jc.2012-1221.
  • Raschke S, Eckel J (2013) Adipo-myokines: two sides of the same coin - mediators of inflammation and mediators of exercise. Mediators Inflamm 2013: 320724. doi: 10.1155/2013/320724.
  • Roden M (2006) Mechanisms of disease: hepatic steatosis in type 2 diabetes - pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2: 335-348. doi: 10.1038/ncpendmet0190.
  • Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40: 1461-1465. doi: 10.1038/ng.257.
  • Roos M, von Eynatten M, Heemann U, Rothenbacher D, Brenner H, Breitling LP (2010) Serum fetuin-A, cardiovascular risk factor, and six-year follow-up outcome in patients with coronary heart disease. Am J Cardiol 105: 1666-1672. doi: 10.1016/j.amjcard.2010.01.342.
  • Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279: 32345-32353. doi: 10.1074/jbc.M313478200.
  • Sato M, Kamada Y, Takeda Y, Kida S, Ohara Y, Fujii H, Akita M, Mizutani K, Yoshida Y, Yamada M, Hougaku H, Takehara T, Miyoshi E (2015) Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int 35: 925-935. doi: 10.1111/liv.12478.
  • Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, Chim AM, Yeung DK, Chan FK, Woo J, Yu J, Chu WC, Wong VW (2012) Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 56: 1363-1370. doi: 10.1016/j.jhep.2011.12.025.
  • Shin JY, Kim SK, Lee MY, Kim HS, Ye BI, Shin YG, Baik SK, Chung CH (2011) Serum sex hormone-binding globulin levels are independently associated with nonalcoholic fatty liver disease in people with type 2 diabetes. Diabetes Res Clin Pract 94: 156-162. doi: 10.1016/j.diabres.2011.07.029.
  • Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson F (2005) A synonymous coding polymorphism in the α2-Heremans-Schmid glycoprotein gene is associated with type 2 diabetes in French Caucasian. Diabetes 54: 2477-2481. doi: 10.2337/diabetes.54.8.2477.
  • Simo R, Saez-Lopez C, Lecube A, Hernandez C, Fort JM, Selva DM (2014) Adiponectin upregulates SHBG production: molecular mechanisms and potential implications. Endocrinology 155: 2820-2830. doi: 10.1210/en.2014-1072.
  • Simo R, Saez-Lopez C, Barbosa-Desongles A, Hernandez C, Selva DM (2015) Novel insights in SHBG regulation and clinical Implication. Trends Endocrinol Metab 26: 376-383. doi: 10.1016/j.tem.2015.05.001.
  • Srinivas PR, Wagner AS, Reddy LU, Deutsch DD, Leon MA, Goustin AS, Grunberger G (1993) Serum α 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 7: 1445-1455. doi: 10.1210/mend.7.11.7906861.
  • Stefan N, Haring HU (2013) The role of hepatokines in metabolism. Nat Rev Endocrinol 9: 144-152. doi: 10.1038/nrendo.2012.258.
  • Stefan N, Haring HU (2013) Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 19: 394-395. doi: 10.1038/nm.3116.
  • Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, Machicao F, Fritsche A, Haring HU (2006) Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29: 853-857. doi: 10.2337/diacare.29.04.06.dc05-1938.
  • Stefan N, Kantartzis K, Haring HU (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29: 939-960. doi: 10.1210/er.2008-0009.
  • Stefan N, Schick F, Haring HU (2009) Sex hormone-binding globulin and risk of type 2 diabetes. N Engl J Med 361: 2675-2676. doi: 10.1056/NEJMc0910143.
  • Stefan N, Schick F, Haring HU (2014) Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 371: 2236-2237. doi: 10.1056/NEJMc1412427#SA3.
  • Stefan N, Sun Q, Fritsche A, Machann J, Schick F, Gerst F, Jeppesen C, Joost HG, Hu FB, Boeing H, Ullrich S, Häring HU, Schulze MB (2014) Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort - and cross-sectional phenotyping studies. PLoS One 9: e92238. doi: 10.1371/journal.pone.0092238.
  • Sutton-Tyrrell K, Wildman RP, Matthews KA, Chae C, Lasley BL, Brockwell S, Pasternak RC, Lloyd-Jones D, Sowers MF, Torrens JL, SWAN investigators (2005) Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factor in multiethnic premenopausal and perimenopausel women enrolled in the Study of Women Across the Nation (SWAN). Circulation 111: 1242-1249. doi: 10.1161/01.CIR.0000157697.54255.CE.
  • Takata H, Ikeda Y, Suehiro T, Ishibashi A, Inoue M, Kumon Y, Terada Y (2009) High glucose induces transactivation of the α2-HS glycoprotein gene through the ERK1/2 signaling pathway. J Atheroscler Thromb 16: 448-456. doi: 10.5551/jat.No950.
  • Tanaka N, Takahashi S, Zhang Y, Krausz KW, Smith PB, Patterson AD, Gonzalez FJ (2015) Role of fibroblast growth factor 21 in early stage of NASH induced by methionine- and choline-deficient diet. Biochim Biophys Acta 1852: 1242-1252. doi: 10.1016/j.bbadis.2015.02.012.
  • Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G (2005) Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54: 3541-3546. doi: 10.2337/diabetes.54.12.3541.
  • Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363: 1341-1350. doi: 10.1056/NEJMra0912063.
  • Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274-285. doi: 10.1111/j.1365-2036.2011.04724.x.
  • Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Haring HU, Boeing H, Fritsche A (2008) Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation 118: 2555-2562. doi: 10.1161/CIRCULATIONAHA.108.814418.
  • Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Veniant MM (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58: 250-259. doi: 10.2337/db08-0392.
  • Yamagoe S, Yamakawa Y, Matsuo Y, Minowada J, Mizuno S, Suzuki K (1996) Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2. Immunol Lett 52: 9-13. doi: 10.1016/0165-2478(96)02572-2.
  • Yamagoe S, Mizuno S, Suzuki K (1998) Molecular cloning of human and bovine LECT2 having a neutrophil chemotactic activity and its specific expression in the liver. Biochem Biophys Acta 1396: 105-113. doi: 10.1016/S0167-4781(97)00181-4.
  • Yan H, Xia M, Chang X, Xu Q, Bian H, Zeng M, Rao S, Yao X, Tu Y, Jia W, Gao X (2011) Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content. PLoS One 6: e24895. doi: 10.1371/journal.pone.0024895.
  • Yang SJ, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM (2011) Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab 96: E1325-E1329. doi: 10.1210/jc.2011-0620.
  • Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E (2010) Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 40: 887-892. doi: 10.1111/j.1365-2362.2010.02338.x.
  • Yilmaz Y, Yonal O, Kurt R, Ari F, Oral AY, Celikel CA, Korkmaz S, Ulukaya E, Ozdogan O, Imeryuz N, Avsar E, Kalayci C (2010) Serum fetuin A/alpha2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Ann Clin Biochem 47: 549-553. doi: 10.1258/acb.2010.010169.
  • Yoo HJ, Choi KM (2015) Hepatokines as a link between obesity and cardiovascular disease. Diabetes Metab J 39: 10-15. doi: 10.4093/dmj.2015.39.1.10.
  • Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI (2002) Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1) - associated phosphatidylinositol 3-kinase activity in the muscle. J Biol Chem 277: 50230-50236. doi: 10.1074/jbc.M200958200.
  • Zhang Y, Lei T, Huang JF, Wang SB, Zhou LL, Yang ZQ, Chen XD (2011) The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol Cell Endocrinol 342: 41-47. doi: 10.1016/j.mce.2011.05.003.
  • Zhang Y, Lei T (2015) Fibroblast growth factor 21 analogs for treating metabolic disorders. Front Endocrinol (Laussanne) 8: 168. doi: 10.3389/fendo.2015.00168.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.